PUBLIC COMPANY
saveKartos Therapeutics Inc
updated 18d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M dealThe purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.biopharma_dive · 1mo ago
- STAT+: More signs that GLP-1s may help with peripheral artery diseaseAnthropic will begin developing drugs, BridgeBio pockets a billion, and more biotech news from The Readoutstat · 1mo ago
- Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot programThe planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.biopharma_dive · 1mo ago
- Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfrontIpsen is earmarking up to $1.75 billion to take Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016. Ipsen will pay $450 million upfront ...endpoints · 1mo ago
comments(0)
5-min edit window · permanent after that